IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Thu

In re Applicant:

Ehud GAZIT

Serial No.:

10/562,852 /

Filed:

April 19, 2006

For:

Peptides Antibodies Directed Thereagainst And Methods

Using Same For Diagnosing And Treating Amyloid-

Associated Diseases

Examiner:

Not Yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1646

Attorney

Docket: 31230

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: December 31, 2006

1

PTO/SB/08a (08-03)

Not Yet Assigned

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwo Reduction Acta Complete if Known

Substitute for form 1449A/PTO Application Number 10/562,852 INFORMATION DISCLOSURE April 19, 2006 Filing Date STATEMENT BY APPLICANT First Named Inventor Ehud GAZIT Art Unit 1646 (use as many sheets as necessary)

Examiner Name

JAN 03 2007

			T =	Attornov Dookst Number	31220
Sheet		1 of	5	Attorney Docket Number	31230
				DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-2002/0086067	04-4-2002	Choi et al.	
	2	US-2002/0151506	10-17-2002	Castillo et al.	
	3	US-2006/0079455	04-13-2006	Gazit et al.	
	4	US-4,331,647	05-25-1982	Goldenberg	
	5	US-4,925,673	05-15-1990	Steiner et al.	
.	6	US-5,013,556	07-7-1991	Woodle et al.	
-	7	US-5,270,163	12-14-1993	Gold et al.	
	8	US-5,475,096	12-12-1995	Gold et al.	
	9	US-5,567,588	10-22-1996	Gold et al.	
	10	US-5,595,877	01-21-1997	Gold et al.	
	11	US-5,637,459	06-10-1997	Burke et al.	
	12	US-5,643,768	01-1-1997	Kawasaki	-
	13	US-5,658,754	08-19-1997	Kawasaki	
	14	US-5,683,867	04-4-1997	Biesecker et al.	
	15	US-5,705,337	06-6-1998	Gold et al.	
	16	US-6,309,669	10-30-2001	Setterstrom et al.	
	17	US-6,326,174	04-4-2001	Joyce et al.	
	18	US-6,610,478	08-26-2003	Takle et al.	
	19	US-6,617,114	09-9-2003	Fowlkes et al.	
	20	US-6,677,153	01-13-2004	Iversen	
	21	US-2006/0079454	04-13-2006	Reches et al.	
•	22	US-2006/0194777	08-31-2006	Gazit et al.	
	23	US-6,359,112	03-19-2002	Kapurniotu et al.	
	24	US-4,036,945	07-19-1977	Haber	
	25	US-4,816,567	03-28-1989	Cabilly et al.	
	26	US-4,946,778	07-7-1990	Ladner et al.	
	27	US-5,545,806	08-13-1996	Lonberg et al	
	28	US-5,545,807	08-13-1996	Surani et al.	
	29	US-5,569,825	10-29-1996	Lonberg et al.	
	30	US-5,625,126	04-29-1997	Lonberg et al.	
	31	US-5,633,425	05-27-1997	Lonberg et al.	
	32	US-5,661,016	08-26-1997	Lonberg et al.	
	33	US-6,251,625	07-26-2001	Bommarius et al.	
	34	US-6,255,286	03-3-2001	Yanai et al.	
	35	US-4,626,540	02-2-1986	Capps et al.	
	36	US-2003/0225155	04-4-2003	Fernandez-Pol et al.	
	37	US-4,970,233	11-13-1990	McHugh	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U	nder the I	'aperwork Kerthettofi Act o	1 1995,	no persons are required to res	pond to a collection of information unless it	
		Substitute for form	1449A	/РТО	Application Number	ete if Known 10/562,852
I	NFO	RMATION D	ISC	CLOSURE	Filing Date	April 19, 2006
5	STA	TEMENT BY	API	PLICANT	First Named Inventor	Ehud GAZIT
	(1	ise as many sheets	as ne	cessary)	Art Unit	1646
	`	•			Examiner Name	Not Yet Assigned
Sheet 2 of 5					Attorney Docket Number	31230
				U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. 1			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (ii}	known)			· · · · · · · · · · · · · · · · · · ·
	38	US-6,593,339		07-15-2003	Eek et al.	
	39	US-5,659,041		08-19-1997	Pollak et al.	
	40	US-2001/041732		11-15-2001	Gurley et al.	
_	41	US-2004/029830		02-12-2004	Herbert	
	42	US-2004/152672		05-5-2004	Carson et al.	
	43	US-3,042,685		03-3-1962	Roussel	
	44	US-2,920,080		05-5-1965	Bucourt et al	
	45	US-3,625,973		07-7-1971	Julia	
	46	US-3,790,596	-	05-5-1974	Shkilkova et al	
	47	US-3,976,639		08-24-1976	Batcho et al.	
	<u> </u>	<u> </u>				

		FOREIGN	N PATENT DOC	UMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	48	PCT WO 02/094857	11-28-2002	Gutheil et al.		
	49	EP 966,975	07-7-2005	Kohno et al.		
	50	PCT WO 2006/006172	01-19-2006	Gazit et al.		
	51	PCT WO 01/45726	06-28-2001	Schmitz		
	52	JP 02-295923	06-6-1990	Taiyo		L
	53	JP 59-044313	03-12-1984	Kimura		
	54	PCT WO 03/077866	09-25-2003	Ash et al.		
	55	JP 60-040061	02-2-1985	Unitika		
	56	PCT WO 97/16191	09-9-1997	Hays et al.		
	57	PCT WO 98/20135	05-14-1998	Fitzgerald et al.		
	58	JP 2000-193661	07-14-2000	Tokyo Rikakikai		
	59	JP 63-044895	02-25-1988	Kyowa Hakko Kogyo		l
	60	PCT WO 2006/027780	03-16-2006	Reches et al.		l
	61	PCT WO 2006/013552	09-9-2006	Gazit et al.		l
	62	PCT WO 2006/018850	02-23-2006	Gazit et al.		l

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Judet the Paper very Reduction Apply 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U	nder the	Paperwork Reduction	Acom/1993,	no persons are required to resp	ond to a collection of information unless it				
		Substitute for	form 1449A	(PTO	Complete if Known				
					Application Number	10/562,852			
I	NFO	DRMATIO!	N DISC	CLOSURE	Filing Date	April 19, 2006			
5	STA	TEMENT I	BY API	PLICANT	First Named Inventor	Ehud GAZIT			
	(use as many sh	eets as nec	cessary)	Art Unit	1646			
					Examiner Name	Not Yet Assigned			
Sheet	eet 3 of 5				Attorney Docket Number	31230			
				U.S. PATENT	DOCUMENTS				
Examiner Initials*	Cite No. 1			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
						Figures Appear			

Cite No. ¹	Foreign Patent Documents		1		
	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
63	PCT WO 2005/027901	03-31-2005	Gazit et al.		
64	PCT WO 03/039540	05-15-2003	Heefner et al.		
65	PCT WO 03/070269	08-28-2003	Schraermeyer		
66	EP 0421946	04-10-1991	Politi et al		_
67	PCT WO 99/42102	08-26-1999	Pappolla		
68	PCT WO 03/024443	03-27-2003	Martynyuk et al		
69	PCT WO 00/24390	04-4-2000	Reiner et al.		
70	PCT WO 2005/016339	02-24-2005	Landreth et al		
71	PCT WO 2005/085867	09-15-2005	Taniguchi et al.		
72	PCT WO 2006/020681	02-23-2006	Banerjee		_
-					
					_
.		1	Date		_
	65 66 67 68 69 70 71 72	65 PCT WO 03/070269 66 EP 0421946 67 PCT WO 99/42102 68 PCT WO 03/024443 69 PCT WO 00/24390 70 PCT WO 2005/016339 71 PCT WO 2005/085867 72 PCT WO 2006/020681	65 PCT WO 03/070269 08-28-2003 66 EP 0421946 04-10-1991 67 PCT WO 99/42102 08-26-1999 68 PCT WO 03/024443 03-27-2003 69 PCT WO 00/24390 04-4-2000 70 PCT WO 2005/016339 02-24-2005 71 PCT WO 2005/085867 09-15-2005 72 PCT WO 2006/020681 02-23-2006	65 PCT WO 03/070269	65 PCT WO 03/070269 08-28-2003 Schraermeyer 66 EP 0421946 04-10-1991 Politi et al 67 PCT WO 99/42102 08-26-1999 Pappolla 68 PCT WO 03/024443 03-27-2003 Martynyuk et al 69 PCT WO 00/24390 04-4-2000 Reiner et al. 70 PCT WO 2005/016339 02-24-2005 Landreth et al 71 PCT WO 2005/085867 09-15-2005 Taniguchi et al. 72 PCT WO 2006/020681 02-23-2006 Banerjee

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nicolated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

Under the Water Space Reduction U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

JAN 0 3 2007

(use as many sheets as necessary)

Cor	nplete if Known
Application Number	10/562,852
Filing Date	April 19, 2006
First Named Inventor	Ehud GAZIT
Group Art Unit	1646

]						
					Examiner Name	Not Yet Assigned					
Sheet	4	of	5		Attorney Docket Number	31230					
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS									
Examiner	Cite	Include name of the aut	hor (in C	CAPITAL LETTERS)	, title of the article (when appro	priate), title of the					
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	73	Appukkuttan et al. "Microwave Enhanced Formation of Electron Rich Arylboronates", Synlett, 8: 1204-1206, 2003. Figs. Scheme 4, Compounds 5A, 5B, 5C, 5D.									
	74	Beugelmans Database Crossfire Beilstein [Online], Beilstein Institut zur F?rderung der Chemischen Wissenschaften, Frankfurt am Main, DE, Database Accession No. 116671 (BRN) Compounds INDOL-2-YL-Methanol & Beugelmans R.: Bulletin de la Soci?t? Chimique Fran?aise, P.335-336, 1969.									
	75	Cohen et al "Inhibiti Hydroxyindole Deri Col.1, Last §, P.472	Cohen et al "Inhibition of Amyloid Fibril Formation and Cytotoxicity by Hydroxyindole Derivatives", Biochemistry, 45: 4727-4735, 2006. Abstract, P.4728, Col.1, Last §, P.4728, Col.2, § 2, Fig.1, P.4729, Col.1, P.4728, Col.1, Last §, P.4728, Col.2, § 2, Fig.1, P.4728, Col.2, § 2, Fig.1, 4, P.4732, Col.2, §								
-	76	Altland et al. "Potential Treatment of Transthyretin-Type Amyloidoses by Sulfite", Neurogenetics, 2: 183-188, 1999.									
	77	Azriel et al. "Analysis of the Minimal Amyloid-Forming Fragment of the Islet Amyloid Polypeptide", The Journal of Biological Chemistry, 276(36): 34156-34161, 2001.									
	78	Pass Metabolism of Present in Beer, After	N-Met er Oral	hyltyramine, A Po Ingestion in Rats	osorption Profile Including tent Stimulant of Gastring by Gastrointestinal-Tran 28(5): 577-581, 2000.	n Release					
	79	Higaki et al. "Regula	ation o Poorl	f Drug Absorptior y Absorbable Dru	From Small Intestine by g Via Passive Diffusion"						
	80		hates: 1	mplications for A	Vivo Using Small-Molect Izheimer's Disease", Nat						
	81	Library of 2,000 Dru 10294, 2003.	igs and	Natural Products	sociated Prion Protein Fo ", Journal of Virology, 7	7(19): 10288-					
	82	Lashuel et al. "New Class of Inhibitors of Amyloid-? Fibril Formation. Implications for the Mechanism of Pathogenesis in Alzheimer's Disease", The Journal of Biological Chemistry, 277(45): 42881-42890, 2002.									
	83				ranilic Acid-Based Trans edicinal Chemistry Letter						
	84	Amyloid Fibril Form	nation"	, Proc. Natl. Acad		2960, 1998.					
XAMINER: Initia	85	Amyloid Fibril Formation", Proc. Natl. Acad. Sci. USA, 95: 12956-12960, 1998. Westwater et al. "Use of Genetically Engineered Phage to Deliver Antimicrobial Agents to Bacteria: An Alternative Therapy for Treatment of Bacterial Infections", Antimicrobial Agents and Chemotherapy, 47 (4): 1301-1307, 2003.									

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Red

Substitute for m 1449A/F INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/562,852 Filing Date April 19, 2006 First Named Inventor **Ehud GAZIT**

	(use	as many sheets as i	iecessa	ıry)	Group Art Unit	1646				
					Examiner Name	Not Yet Assigned				
Sheet	5		of	5	Attorney Docket Number	31230	_			
		OTHER F	RIOR	ART – NON PATEN	T LITERATURE DOCL	JMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
	86	Gazit "A Possible Role for 'Phi'-Stacking in the Self-Assembly of Amyloid Fibrils", The FASEB Journal, 16: 77-83, 2002.								
	87	Soto et al. Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in A Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy", Nature Medicine, 4(7): 822-826, 1998.								
	88	Inglot "Comparison of the Antiviral Activity In Vitro of Some Non-Steroidal Anti-Inflammatory Drugs", Journal of General Virology, 4(2): 203-214, 1969.								
	89	Pavia et al. "Antimicrobial Activity of Nicotine Against A Spectrum of Bacterial and Fungal Pathogens", Journal of Medical Microbiology, 49(7): 675-676, 2000.								
	90	Nakajima "Amin	e Prec Acid"	ursor Therapy: Manip , Psychiatry and Clin	oulation of Brain Amine A ical Neurosciences, 51(5)	Activity With				
	91	Lee et al. "Anti-Diabetic Constituent From the Node of Lotus Rhizome (Nelumbo Nucifera Gaertn)", Natural Product Sciences, 7(4), 107-109, 2001. P.108, Col.1, Last § - Col.2, § 1.								
	92	Honma et al. "Use of A Thromboxane A2 Antagonist or Synthase Inhibitor for Treating Central Nervous System Diseases, e.g. Alzheimer Type Dementia." Database WPI, Section Ch. Week 200039, Derwent Publications, Class B05, AN 2000-451668. & WO 00/30683 (Yagami et al.), 2 June 2000. Abstract.								
	93	Losert et al. "Effect of Indole 3 Alkanecarboxylic Acifs on Glucose Utilization in Rats" Arzneimittel-Forschung/Drug Research, 25(6): 880-887, 1975. P.880, Col.1, § 6, P.886, Col.2, § 4, 5, P.887, Col.1, § 3.								
	94	Cervix Dysplasia and Treatment of	and C Said S erwent	ancer and Larynx Pa Sicknesses Based on Publications, Class I	ophylaxis and Treatment pillomatosis and Methods Thereof", Database WPI, B02, AN 2003-286683 &	of Prophylaxis Section Ch,				
_	95	Kon-Ya et al "In-	dole Do	erivatives as Potent In hitrite", Bioscience E	nhibitors of Larval Settler Biotechnology Biochemist					
		1								

Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.